← Back to Clinical Trials
Recruiting NCT06476795

The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Cardiovascular Diseases
Sponsor University of California, Davis
Study Type INTERVENTIONAL
Phase N/A
Enrollment 5
Sex FEMALE
Min Age 45 Years
Max Age 70 Years
Start Date 2024-06-01
Completion 2026-06
Interventions
Chardonnay Marc

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.

Eligibility Criteria

Inclusion Criteria: * Postmenopausal female, with a cessation of menses for at least 2 years * 45-70 years of age * BMI 25- 49.9 kg/m2 * Fasting triglycerides \> 120 mg/dL * Subject is willing and able to comply with the study protocols and procedures. Exclusion Criteria: * Self-reported use of daily anticoagulation agents including aspirin, NSAIDs * Prescription medications and supplements, except for a 6 month stable dose of thyroid medications * Vegan, Vegetarians, food faddists or those consuming a non-traditional diet * Fruit consumption ≥ 3 cups/day * Vegetable consumption ≥ 4 cups/day * Coffee/tea ≥ 3 cups/day * Dark chocolate ≥ 3 oz/day * Self-reported restriction of physical activity due to a chronic health condition * Self-reported chronic/routine high intensity exercise * Blood pressure ≥ 140/90 mm Hg * Self-reported renal or liver disease * Self-reported heart disease, which includes cardiovascular events and stroke, diabetes * Peripheral artery disease Raynaud's syndrome o

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}